BLK vs PFE: Which Is the Better Buy?
Side-by-side comparison of BlackRock, Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-15.
BlackRock, Inc. · Financial Services
$1,025.44
+31.0% upside to fair value
Grade A
High Quality
VS
Pfizer Inc. · Healthcare
$25.22
+2.8% upside to fair value
Grade B
QuantHub Verdict
BLK has more upside to fair value
(+31.0%).
PFE trades at a lower forward P/E
(19.2x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
BLK |
PFE |
| Current Price |
$1,025.44 |
$25.22 |
| Fair Value Estimate |
$1,343.02 |
$25.92 |
| Upside to Fair Value |
+31.0%
|
+2.8%
|
| Market Cap |
$158.9B |
$143.7B |
| Forward P/E |
24.2x
|
19.2x
|
| EV / EBITDA |
16.0x
|
12.3x
|
| Price / Sales |
5.8x
|
2.3x
|
| Price / FCF |
44.6x
|
15.2x
|
| Revenue Growth YoY |
+30.6%
|
+5.4%
|
| Gross Margin |
54.6%
|
69.3%
|
| Operating Margin |
32.9%
|
23.4%
|
| Return on Equity |
12.5%
|
8.4%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
2.24%
|
6.6%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
BlackRock, Inc. is a leading global asset management firm operating within the financial services sector, specializing in investment management and risk advisory. The company demonstrates high business quality with a durable competitive moat supported by strong brand recognition, intangible assets, and switching costs. It reported robust growth in the most recent quarter with revenue up 30.6% yea…
Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…
Accumulation Zones
| Metric |
BLK |
PFE |
| Zone Low |
$1,007.26 |
$19.44 |
| Zone High |
$1,141.57 |
$22.03 |
| In Buy Zone? |
Yes
|
No
|